SARS-CoV-2 enters cells via binding of the surface-exposed spike protein RBD to host cell
ACE2 receptors. Therefore, in this study, we designed a scFv (single-chain fragment …

In 2020 and 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel
coronavirus, caused a global pandemic. Vaccines are expected to reduce the pressure of …

COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2. From its initial
appearance in Wuhan, China in 2019, it developed rapidly into a global pandemic. In …

Abstract Aim and Background: COVID-19, an infectious viral disease caused by severe
acute respiratory syndrome (SARS-CoV-2) with more than 260 million infections as of …

As the second wave of COVID-19 launched, various variants of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) have emerged with a dramatic global spread …

Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-
2 receptor binding domain (RBD, residues 319–541) and a mouse IgG1 Fc domain, could …

SARS‐CoV‐2 is responsible for a disruptive worldwide viral pandemic, and renders a
severe respiratory disease known as COVID‐19. Spike protein of SARS‐CoV‐2 mediates …

Many efforts have been made around the world to combat SARS-CoV-2. Among these are
recombinant antibodies considered to be suitable as an alternative for some diagnostics …

The aim of the study is to synthesize a recombinant protein in Escherichia coli cells that
carries the receptor-binding domain (RBD) of Spike protein of SARS CoV-2, with antiviral …

The COVID-19 pandemic caused by SARS-CoV-2 has applied significant pressure on
overtaxed healthcare around the world, underscoring the urgent need for rapid diagnosis …